semaglutide in kidney disease Effects of on Chronic Patients with Type 2 Diabetes | NEJM clinicaltrials #medicalresearch | NEJM Group

Clinical trials with FDA-approved semaglutide showed participants losing an average of 15-20% of their body weight over 68-72 weeks

This can be uncomfortable and concerning, but there are ways to help prevent this side effect

AMPK activation in the VMH decreases energy expenditure (105107) and AMPK inhibition increases energy expenditure ( Figure 1 )

Este frmaco acta estimulando la liberacin de insulina en funcin de los niveles de glucosa en sangre y la cantidad de alimentos ingeridos, lo que permite reducir considerablemente el riesgo de hipoglucemia, evitando que los niveles de azcar en sangre disminuyan de manera peligrosa cuando no hay nutrientes presentes

cAMP activates protein kinase A, resulting in closure of ATP-sensitive potassium channels and depolarization of beta cells, leading to the opening of voltage-gated calcium channels on the cell membrane and exocytosis of insulin-containing granules released from the endoplasmic reticulum due to calcium release [36]